LT3788044T - Rip1 inhibitoriniai junginiai ir jų gamybos bei naudojimo būdai - Google Patents

Rip1 inhibitoriniai junginiai ir jų gamybos bei naudojimo būdai

Info

Publication number
LT3788044T
LT3788044T LTEPPCT/US2019/030476T LTUS2019030476T LT3788044T LT 3788044 T LT3788044 T LT 3788044T LT US2019030476 T LTUS2019030476 T LT US2019030476T LT 3788044 T LT3788044 T LT 3788044T
Authority
LT
Lithuania
Prior art keywords
making
methods
same
inhibitory compounds
rip1
Prior art date
Application number
LTEPPCT/US2019/030476T
Other languages
English (en)
Inventor
Esteban Masuda
Simon Shaw
Vanessa Taylor
Somasekhar Bhamidipati
Original Assignee
Rigel Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals, Inc. filed Critical Rigel Pharmaceuticals, Inc.
Publication of LT3788044T publication Critical patent/LT3788044T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D267/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02Seven-membered rings
    • C07D267/08Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
LTEPPCT/US2019/030476T 2018-05-03 2019-05-02 Rip1 inhibitoriniai junginiai ir jų gamybos bei naudojimo būdai LT3788044T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862666462P 2018-05-03 2018-05-03
PCT/US2019/030476 WO2019213447A1 (en) 2018-05-03 2019-05-02 Rip1 inhibitory compounds and methods for making and using the same

Publications (1)

Publication Number Publication Date
LT3788044T true LT3788044T (lt) 2023-11-10

Family

ID=66530556

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2019/030476T LT3788044T (lt) 2018-05-03 2019-05-02 Rip1 inhibitoriniai junginiai ir jų gamybos bei naudojimo būdai

Country Status (36)

Country Link
US (7) US10815206B2 (lt)
EP (2) EP4248975A3 (lt)
JP (4) JP2021523226A (lt)
KR (1) KR20210005222A (lt)
CN (1) CN112368278A (lt)
AU (2) AU2019262144B2 (lt)
BR (1) BR112020022420A2 (lt)
CA (1) CA3099037A1 (lt)
CL (1) CL2020002841A1 (lt)
CO (1) CO2020015156A2 (lt)
CR (1) CR20200581A (lt)
DK (1) DK3788044T3 (lt)
DO (2) DOP2020000198A (lt)
EA (1) EA202092580A1 (lt)
EC (1) ECSP20078326A (lt)
ES (1) ES2956087T3 (lt)
FI (1) FI3788044T3 (lt)
HR (1) HRP20231381T1 (lt)
HU (1) HUE063896T2 (lt)
IL (2) IL278417B2 (lt)
JO (1) JOP20200278A1 (lt)
LT (1) LT3788044T (lt)
MA (1) MA52488B1 (lt)
MD (1) MD3788044T2 (lt)
MX (1) MX2020011621A (lt)
PE (1) PE20211383A1 (lt)
PH (1) PH12020551847A1 (lt)
PL (1) PL3788044T3 (lt)
PT (1) PT3788044T (lt)
RS (1) RS64736B1 (lt)
SA (1) SA520420468B1 (lt)
SG (1) SG11202010915XA (lt)
SI (1) SI3788044T1 (lt)
UA (1) UA128369C2 (lt)
WO (1) WO2019213447A1 (lt)
ZA (2) ZA202007486B (lt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS64736B1 (sr) 2018-05-03 2023-11-30 Rigel Pharmaceuticals Inc Jedinjenja inhibitori rip1 i postupci za njihovo dobijanje i upotrebu
HRP20230909T1 (hr) 2018-05-03 2023-12-08 Rigel Pharmaceuticals, Inc. Spojevi inhibitori rip1 i postupci za njihovo dobivanje i upotrebu
CN111138448B (zh) * 2018-11-02 2022-08-02 中国科学院上海药物研究所 抑制rip1激酶的杂环酰胺及其用途
WO2020088194A1 (zh) * 2018-11-02 2020-05-07 中国科学院上海药物研究所 抑制rip1激酶的杂环酰胺及其用途
US20210040115A1 (en) * 2019-08-09 2021-02-11 Bisichem Co., Ltd. Fused ring heteroaryl compounds as ripk1 inhibitors
MX2022002717A (es) * 2019-09-06 2022-08-10 Rigel Pharmaceuticals Inc Compuestos inhibidores de rip1 y metodos para prepararlos y usarlos.
WO2021046447A1 (en) 2019-09-06 2021-03-11 Rigel Pharmaceuticals, Inc. Heterocyclic rip1 kinase inhibitors
WO2021046515A1 (en) 2019-09-06 2021-03-11 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase i for the treatment of disease
MX2022003671A (es) 2019-09-27 2022-04-25 Univ Texas Inhibidores de proteina cinasa i de interaccion con receptores para el tratamiento de enfermedades.
CN113015974B (zh) * 2019-10-21 2024-05-28 谷歌有限责任公司 针对隐私保护的可验证同意
JP7395730B2 (ja) 2019-11-07 2023-12-11 ライジェル ファーマシューティカルズ, インコーポレイテッド ヘテロ環式rip1阻害化合物
BR112022010082A2 (pt) * 2019-11-26 2022-08-30 Univ Texas Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, uso do composto e uso da composição farmacêutica
CA3169099A1 (en) * 2020-02-28 2021-09-02 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase i for the treatment of disease
AR121717A1 (es) 2020-04-02 2022-06-29 Rigel Pharmaceuticals Inc Inhibidores de rip1k
TWI824259B (zh) 2020-07-01 2023-12-01 美商雷傑製藥公司 Rip1k抑制劑
WO2022171111A1 (en) * 2021-02-10 2022-08-18 Zai Lab (Us) Llc Heteroaryl-fused bicyclic compound as rip1-kinase inhibitors and uses thereof
CN114989156B (zh) * 2021-05-19 2024-07-05 成都贝诺科成生物科技有限公司 一种受体相互作用蛋白抑制剂及其制备方法和用途
BR112023025850A2 (pt) 2021-08-10 2024-03-05 Abbvie Inc Inibidores da nicotinamida ripk1
CN118510774A (zh) 2021-12-16 2024-08-16 里格尔药品股份有限公司 Ripk1抑制剂的结晶形式
WO2023138317A1 (zh) * 2022-01-21 2023-07-27 中国科学院上海药物研究所 具有ripk1抑制活性的化合物、其制备方法及其用途
CN114736197B (zh) * 2022-06-13 2022-09-13 南京医工医药技术有限公司 咪唑啉酮衍生物及其用途
CN115353513A (zh) * 2022-07-29 2022-11-18 中国人民解放军海军军医大学 一种抑制程序性细胞坏死的硫代七元环衍生物及其应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
ATE107176T1 (de) 1989-12-04 1994-07-15 Searle & Co System zur transdermalen albuterol applikation.
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
EP0495421B1 (en) 1991-01-15 1996-08-21 Alcon Laboratories, Inc. Use of carrageenans in topical ophthalmic compositions
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
CA2123809A1 (en) 1991-12-18 1993-06-24 Debra L. Wilfong Multilayered barrier structures
EP0553769B1 (de) 1992-01-29 1996-01-03 FRANZ VÖLKL GmbH & CO. SKI UND TENNIS SPORTARTIKELFABRIK KG Ballspielschläger, insbesondere Tennisschläger
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
EP2192838A4 (en) 2007-08-15 2011-07-27 Harvard College HETEROCYCLIC NEKROPTOSIS HEMMER
TWI648273B (zh) 2013-02-15 2019-01-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類(三)
EP2968276A4 (en) 2013-03-15 2017-02-15 President and Fellows of Harvard College Hybrid necroptosis inhibitors
WO2016027253A1 (en) * 2014-08-21 2016-02-25 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as rip1 kinase inhibitors as medicaments
WO2016128936A1 (en) 2015-02-13 2016-08-18 Glaxosmithkline Intellectual Property Development Limited Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide
CN112979660A (zh) * 2015-07-02 2021-06-18 豪夫迈·罗氏有限公司 二环内酰胺和其应用方法
PL3362449T3 (pl) 2015-10-13 2021-12-13 Institut National De La Santé Et De La Recherche Médicale (Inserm) Pochodne sybiriliny do zastosowania do zapobiegania i/lub leczenia zaburzeń związanych z nekroptozą komórkową
EP3366684B1 (en) 2015-10-23 2020-09-02 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2017109724A1 (en) 2015-12-21 2017-06-29 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
CN109071504B (zh) 2016-02-05 2022-03-08 戴纳立制药公司 受体相互作用蛋白激酶1的抑制剂
EP3526219B1 (en) * 2016-10-17 2021-12-15 F. Hoffmann-La Roche AG Bicyclic pyridone lactams and methods of use thereof
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
CN110573504A (zh) 2017-02-27 2019-12-13 葛兰素史克知识产权开发有限公司 作为激酶抑制剂的杂环酰胺
RS64736B1 (sr) * 2018-05-03 2023-11-30 Rigel Pharmaceuticals Inc Jedinjenja inhibitori rip1 i postupci za njihovo dobijanje i upotrebu
HRP20230909T1 (hr) * 2018-05-03 2023-12-08 Rigel Pharmaceuticals, Inc. Spojevi inhibitori rip1 i postupci za njihovo dobivanje i upotrebu
TW202019913A (zh) 2018-06-26 2020-06-01 中國科學院上海有機化學研究所 細胞壞死抑制劑及其製備方法和用途
CN111138448B (zh) 2018-11-02 2022-08-02 中国科学院上海药物研究所 抑制rip1激酶的杂环酰胺及其用途
WO2020088194A1 (zh) 2018-11-02 2020-05-07 中国科学院上海药物研究所 抑制rip1激酶的杂环酰胺及其用途
WO2021046447A1 (en) 2019-09-06 2021-03-11 Rigel Pharmaceuticals, Inc. Heterocyclic rip1 kinase inhibitors
AR121717A1 (es) 2020-04-02 2022-06-29 Rigel Pharmaceuticals Inc Inhibidores de rip1k

Also Published As

Publication number Publication date
EA202092580A1 (ru) 2021-04-07
EP3788044A1 (en) 2021-03-10
JP2022160665A (ja) 2022-10-19
RS64736B1 (sr) 2023-11-30
HRP20231381T1 (hr) 2024-03-01
AU2019262144A1 (en) 2020-11-26
ES2956087T3 (es) 2023-12-13
US20210040053A1 (en) 2021-02-11
US20210002236A1 (en) 2021-01-07
IL299784B2 (en) 2024-04-01
US20230113841A1 (en) 2023-04-13
EP4248975A2 (en) 2023-09-27
PE20211383A1 (es) 2021-07-27
US20200407332A1 (en) 2020-12-31
HUE063896T2 (hu) 2024-02-28
US20210009537A1 (en) 2021-01-14
CA3099037A1 (en) 2019-11-07
MD3788044T2 (ro) 2023-12-31
JP2023022225A (ja) 2023-02-14
US11332451B2 (en) 2022-05-17
BR112020022420A2 (pt) 2021-03-02
MA52488A (fr) 2021-03-10
WO2019213447A1 (en) 2019-11-07
CN112368278A (zh) 2021-02-12
US12116354B2 (en) 2024-10-15
PH12020551847A1 (en) 2021-06-28
JP7367169B2 (ja) 2023-10-23
JP2021523226A (ja) 2021-09-02
SG11202010915XA (en) 2020-12-30
JOP20200278A1 (ar) 2020-11-03
CR20200581A (es) 2021-05-11
ZA202108603B (en) 2022-03-30
EP4248975A3 (en) 2024-03-13
AU2023254980A1 (en) 2023-11-16
MX2020011621A (es) 2021-02-22
SI3788044T1 (sl) 2023-12-29
US11472782B2 (en) 2022-10-18
IL278417A (lt) 2020-12-31
DOP2020000198A (es) 2021-04-30
DK3788044T3 (da) 2023-10-02
IL278417B2 (en) 2024-05-01
US20210238153A2 (en) 2021-08-05
IL278417B1 (en) 2024-01-01
KR20210005222A (ko) 2021-01-13
JP2024009916A (ja) 2024-01-23
SA520420468B1 (ar) 2024-04-28
JP7187729B2 (ja) 2022-12-12
CO2020015156A2 (es) 2021-02-26
PT3788044T (pt) 2023-08-31
US11370764B2 (en) 2022-06-28
US20210002237A1 (en) 2021-01-07
EP3788044B1 (en) 2023-08-09
MA52488B1 (fr) 2023-11-30
IL299784B1 (en) 2023-12-01
PL3788044T3 (pl) 2024-02-12
ZA202007486B (en) 2022-06-29
CL2020002841A1 (es) 2021-05-24
ECSP20078326A (es) 2021-03-31
FI3788044T3 (fi) 2023-09-25
US11377428B2 (en) 2022-07-05
DOP2023000169A (es) 2023-10-15
US11370765B2 (en) 2022-06-28
UA128369C2 (uk) 2024-06-26
US10815206B2 (en) 2020-10-27
AU2019262144B2 (en) 2023-11-16
IL299784A (en) 2023-03-01
US20190337907A1 (en) 2019-11-07

Similar Documents

Publication Publication Date Title
ZA202108603B (en) Rip1 inhibitory compounds and methods for making and using the same
IL291033A (en) rip1 inhibitory compounds and methods for their preparation and use
ZA202007487B (en) Rip1 inhibitory compounds and methods for making and using the same
IL290781A (en) rip1 inhibitory compounds and methods for their preparation and use
EP3746124A4 (en) COMPOUNDS AND USES THEREOF
LT3594199T (lt) Kristalinis 2-fluor-3-nitroluenas ir jo paruošimo būdas
SG11202009138QA (en) Silicon-terminated organo-metal compounds and processes for preparing the same
SG11202009175RA (en) Silicon-terminated organo-metal compounds and processes for preparing the same
IL277502A (en) Compounds and uses for them
EP3853216A4 (en) PYRIDINYL SUBSTITUTE COMPOUNDS AND THEIR USES
EP3899293A4 (en) LOCK NUT
IL283309A (en) rip1 inhibitors
IL279483A (en) Cyanotriazole compounds and their uses
EP3724933A4 (en) SUPRAL CONDUCTING COMPOUNDS AND METHOD FOR PRODUCING THEREOF
EP3743635A4 (en) ANTI-KICKBACK LOCK
GB201917427D0 (en) The flylead
GB201916822D0 (en) The degravitator
EP3883564A4 (en) CONNECTIONS AND USES THEREOF
ZA201906782B (en) Mulcher
GB201904750D0 (en) The dehydrometer
GB201902293D0 (en) The hangit
GB201808686D0 (en) The dogtooth
AU2018902788A0 (en) 2018-05-25 6d
AU2018903548A0 (en) Substituted-pyridinyl compounds and uses thereof
GB201800634D0 (en) The Tasteaire